Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children

British Journal of Haematology

Volumn 149, Issue 5, 2010, Pages 734-738

  Ignjatovic, Vera ^a,b   Najid, Siti ^b   Newall, Fiona ^b,c   Summerhayes, Robyn ^a,b   Monagle, Paul ^a,b,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Anti Xa assay; Children; Enoxaparin; Low molecular weight heparins; Therapeutic dose

Indexed keywords

BLOOD CLOTTING FACTOR 10; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; AGE; ARTICLE; BLEEDING; BLOOD CLOT; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; DRUG TARGETING; FEMALE; HUMAN; IMMUNOASSAY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THROMBOEMBOLISM;

ADOLESCENT; AGE DISTRIBUTION; AGE FACTORS; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 77952655437     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08163.x     Document Type: Article

References (19)

1. Bauman, M.E., Belletrutti, M.J., Bajzar, L., Black, K.L., Kuhle, S., Bauman, M.L. Massicotte, M.P. (2009) Evaluation of enoxaparin dosing requirements in infants and children: better dosing to achieve therapeutic levels. Thrombosis and Haemostasis, 101, 86 92.
2. Bontadelli, J., Moeller, A., Schmugge, M., Schraner, T., Kretschmar, O., Bauersfeld, U., Bernet-Buettiker, V. Albisetti, M. (2007) Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease. Intensive Care Medicine, 33, 1978 1984.
3. Burak, C.R., Bowen, M.D. Barron, T.F. (2003) The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatric Neurology, 29, 295 298.
4. Chalmers, E.A. (2006) Epidemiology of venous thromboembolism in neonates and children. Thrombosis Research, 118, 3 12.
5. Dix, D., Andrew, M., Marzinotto, V., Charpentier, K., Bridge, S., Monagle, P., De Veber, G., Leaker, M., Chan, A.K. Massicotte, M.P. (2000) The use of low molecular weight heparin in pediatric patients: a prospective cohort study. The Journal of Pediatrics, 136, 439 445.
6. Ho, S.H., Wu, J.K., Hamilton, D.P., Dix, D.B. Wadsworth, L.D. (2004) An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. Journal of Pediatric Hematology/Oncology, 26, 561 566.
7. Malowany, J.I., Knoppert, D.C., Chan, A.K., Pepelassis, D. Lee, D.S. (2007) Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy, 27, 1263 1271.
8. Manco-Johnson, M. (2006) How I treat venous thrombosis in children. Blood, 107, 21 29.
9. Massicotte, P., Adams, M., Marzinotto, V., Brooker, L.A. Andrew, M. (1996) Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. Journal of Pediatrics, 128, 313 318.
10. Massicotte, P., Julian, J., Gent, M., Shields, K., Marzinotto, V., Szechtmanb, B., Chan, A.K. Andrew, M. (2003) An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thrombosis Research, 109, 101 108. (Pubitemid 36428760)
11. McCusker, P.J., Seifert, B.W. Israels, S.J. (2003) Higher doses of enoxaparin are required to achieve therapeutic heparin (aXa) levels in neonates (NBs) with venous thromboembolic disease (VTE). Blood, 102, 1155.
12. Michaels, L.A., Gurian, M., Hegyi, T. Drachtman, R.A. (2004) Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics, 114, 703 707.
13. Monagle, P., Chalmers, E., Chan, A., DeVeber, G., Kirkham, F., Massicotte, P. Michelson, A.D. (2008) Antithrombotic therapy in neonates and children. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 133, 887S 968S.
14. Nohe, N., Flemmer, A., Rümler, R., Praun, M. Auberger, K. (1999) The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. European Journal of Pediatrics, 158, S134 S139.
15. O'Brien, S.H., Lee, H. Ritchey, A.K. (2007) Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. Journal of Thrombosis and Haemostasis, 5, 1985 1987.
16. Punter, F., Seshia, M., Israels, S.J. Seifert, B.W. (2004) Retrospective analysis of the minimum dosage requirements for enoxaparin in neonates with thromboembolic disease. Blood, 104, Abstract 1770.
17. Punzalan, R.C., Hillery, C.A., Montgomery, R.R., Scott, J.P. Gill, J.C. (2000) Low-molecular-weight heparin in thrombotic disease in children and adolescents. Journal of Pediatric Hematology Oncology, 22, 137 142.
18. Revel-Vilk, S., Sharathkumar, A., Massicotte, P., Marzinotto, V., Daneman, A., Dix, D. Chan, A. (2004) Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. Journal of Thrombosis and Haemostasis, 2, 42 46.
19. Streif, W., Goebel, G., Chan, A. Massicotte, M.P. (2003) Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Archives of Disease in Childhood. Fetal and Neonatal Edition, 88, F365 F370.